Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00151502 · ClinicalTrials.gov registry record · Phase 3

To Evaluate the Safety and Effectiveness of Atorvastatin Plus a Cholinesterase Inhibitor in AD Patients.

A Phase 3 study of Alzheimers Disease, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.

Completed
Registry status
Phase 3
Development phase
600
Enrollment target
20
Study locations

NCT00151502 is a Phase 3 study of Alzheimers Disease that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 600 participants, below the 4,057-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00151502, a Phase 3 study of Alzheimers Disease, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.

COMPLETED
Registry status
Phase 3
Development phase
600 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to find out if atovastatin, when taken with a cholinesterase inhibitor, is effective for treating Alzheimer's disease.

Conditions Studied

Alzheimers Disease

Interventions

  • DRUG Atorvastatin

Study Locations (20)

Florida

  • Pfizer Investigational Site - Fort Lauderdale
  • Pfizer Investigational Site - Fort Myers
  • Pfizer Investigational Site - Miami Beach
  • Pfizer Investigational Site - Pompano Beach
  • Pfizer Investigational Site - St. Petersburg
  • Pfizer Investigational Site - West Palm Beach

California

  • Pfizer Investigational Site - Fresno
  • Pfizer Investigational Site - Laguna Hills
  • Pfizer Investigational Site - San Francisco

Massachusetts

  • Pfizer Investigational Site - South Dartmouth
  • Pfizer Investigational Site - West Yarmouth
  • Pfizer Investigational Site - Worcester

New Jersey

  • Pfizer Investigational Site - Jamesburg
  • Pfizer Investigational Site - Princeton

Arizona

  • Pfizer Investigational Site - Sun City

Indiana

  • Pfizer Investigational Site - Fort Wayne

Kentucky

  • Pfizer Investigational Site - Paducah

Louisiana

  • Pfizer Investigational Site - New Orleans

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 2002-11
Est. Completion 2007-07
Phase Phase 3

Sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris

158 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00151502

The ClinicalTrials.gov registry entry for NCT00151502 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,057-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (85% lower). The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 1 intervention - of which Atorvastatin is the first listed.

NCT00151502 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, California, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00151502 about?

NCT00151502 is a clinical study titled "To Evaluate the Safety and Effectiveness of Atorvastatin Plus a Cholinesterase Inhibitor in AD Patients.". The purpose of this study is to find out if atovastatin, when taken with a cholinesterase inhibitor, is effective for treating Alzheimer's disease.

What is the current status of trial NCT00151502?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2002-11. Estimated completion is 2007-07.

What conditions does trial NCT00151502 study?

This clinical trial studies the following conditions: Alzheimers Disease.

What interventions are being tested in trial NCT00151502?

The interventions under investigation include: Atorvastatin (DRUG).

Who is sponsoring clinical trial NCT00151502?

This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00151502 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Indiana, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alzheimers Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Alzheimers Disease

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.